Coherent Market Insights published a business research report on Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2022–2028. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market with 150+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. The information is gathered based on modern floats and requests identified with the administrations and items.
The global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market analysis further provides pioneering landscape of market along with market augmentation history and key development involved in the industry. The report also features comprehensive research study for high growth potential industries professional survey with market analysis. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market report helps the companies to understand the market trends and future market prospective,opportunities and articulate the critical business strategies.
Get Sample Report with Latest Covid19 Impact Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/4321
Market Overview:
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is an under-recognized cause of heart failure in older adults. Transthyretin amyloidosis (ATTR) is a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body’s organs and tissues. ATTR-CM is a type of ATTR that affects the heart and leads to restrictive cardiomyopathy and progressive heart failure. It is generally a rare, underdiagnosed, life-threatening disease. ATTR-CM often causes symptoms of heart failure, such as peripheral edema, shortness of breath, fatigue, and other symptoms related to buildup of amyloid fibrils in the body. There are two types of ATTR-CM, such as wild type transthyretin amyloidosis (wtATTR) and hereditary transthyretin amyloidosis (hATTR). ATTR-CM is often diagnosed only after symptoms have become severe.
Competitive Landscape:
Major players operating in the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are Corino Therapeutics, Inc., Intellia Therapeutics, Prothena Corporation, Alnylam Pharmaceuticals, Eidos Therapeutics, GlaxoSmithKline Plc., Pfizer Inc., and Ionis Pharmaceuticals, Inc., among others.
Key Market Drivers:
High prevalence of ATTR-CM and growing geriatric population around the world is expected to propel growth of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market during the forecast period. ATTR-CM) is an under-recognized cause of heart failure in older adults. For instance, according to the World Health Organization (WHO), by 2030, one in six people in the world will be aged 60 years or over, and the world’s population of people aged 60 years and older will double (2.1 billion) by 2050.
Moreover, increasing number of clinical trials and increase in research and development is expected to boost growth of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market. For instance, in November 2020, Eidos Therapeutics initiated Phase III clinical trial to evaluate the efficacy of Acoramidis in treating adults with ATTR-CM. Top-line results from part A of the trial, called ATTRibute-CM (NCT03860935), are expected in late 2021 or early 2022, and from part B in 2023.
COVID-19 Impact Analysis:
The outbreak of COVID-19 (pandemic) has affected the economy in several ways, such as by directly affecting production and demand and by creating disruptions in distribution channels, among others. The pandemic has disrupted the production, demand, and supply of healthcare products. Moreover, the pandemic has affected the supply of raw materials & other compounds used to manufacture ATTR-CM drugs. This in turn is expected to hinder growth of the market.
Key Takeaways:
- The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market is expected to exhibit a CAGR of 31.1% over the forecast period due to the increasing demand for ATTR-CM treatment. For instance, in May 2019, Pfizer announced that the U.S. Food and Drug Administration (FDA) has approved both VYNDAQEL and VYNDAMAX to treat ATTR-CM and to reduce cardiovascular mortality and cardiovascular-related hospitalization.
- Among regions, North America, Europe, and Asia Pacific are expected to witness robust growth in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market owing to the increasing prevalence of ATTR-CM, ongoing research and development activities, increasing number of clinical trials, frequent approvals/launches, and increasing awareness among people about available ATTR-CM treatment.
For instance, in February 2020, Pfizer Inc. announced that the European Commission (EC) has approved VYNDAQEL (tafamidis), a once-daily 61 mg oral capsule, for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with ATTR-CM.
Buy This Report With USD 2000 Flat OFF – https://www.coherentmarketinsights.com/promo/buynow/4321
Table of Content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Industry Impact
Chapter 2 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment (Volume and Value) by Type
2.3 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Analysis
Chapter 6 East Asia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Analysis
Chapter 7 Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Analysis
Chapter 8 South Asia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Analysis
Chapter 9 Southeast Asia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Analysis
Chapter 10 Middle East Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Analysis
Chapter 11 Africa Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Analysis
Chapter 12 Oceania Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Analysis
Chapter 13 South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Business
Chapter 15 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology
Continued….
Get PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/4321
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837